RISFAX May 21, 2018
日本語- Prof. Matsumura of Kyoto University Hospital: Regarding drugs prepared within hospital, they should be made by drug companies as much as possible
- Chairman Hamada of Toho HD: “Will actively consider” capital tie-up with promising bio-venture companies
- JCR to initiated Phase III of “GROWJECT” for short-stature homeobox-containing gene (SHOX) deficiency in July
- Nissui Pharmaceutical to increase its stake in the bio-venture company originated from Chiba University
- Chiba District Court gives sentence of one year and six months in prison, suspended for three years, to former pharmacist of Welcia Pharmacy
- Toho HD: “Price lock” per product by Messrs. Udoh and Umada in combination
- ViiV Healthcare K.K.: Mr. Dustin Haines, marketing head at UK HQ, to become new president